Inhibitor Therapeutics, Inc.
INTI
Rank in Stocks
#27689
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Share Price
$0.08
Last synced: 2026-11-10
Market Cap
$13.86M
Change (1 day)
1.27%
Change (1 year)
60.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Inhibitor Therapeutics, Inc. (INTI)
Category
Healthcare
Operating Margin for Inhibitor Therapeutics, Inc. (INTI)
Operating Margin as of November 2026 TTM: 0.00%
According to Inhibitor Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Inhibitor Therapeutics, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | 14,865.99% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | -100.00% |
| 2010 | -68.17% | 24.38% |
| 2009 | -54.81% | -40.67% |
| 2008 | -92.38% | 307.68% |
| 2007 | -22.66% | 54.36% |
| 2006 | -14.68% | -553.09% |
| 2005 | 3.24% | -28.79% |
| 2004 | 4.55% | 50.17% |
| 2003 | 3.03% | -139.40% |
| 2002 | -7.69% | -72.27% |
| 2001 | -27.73% | 91.24% |
| 2000 | -14.50% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Inhibitor Therapeutics, Inc.'s operating margin
What was Inhibitor Therapeutics, Inc.'s operating margin in 2025?
In 2025, Inhibitor Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Inhibitor Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Inhibitor Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Inhibitor Therapeutics, Inc.'s operating margin compare with similar companies?
Inhibitor Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.